Xbrane Biopharma AB (publ) has carried out a major issuance of shares of roughly SEK 125 million the place the subscription worth was decided by an accelerated bookbuilding process. In connection hereto, Xbrane has concluded on a convertible bond financing implying internet proceeds of SEK 225 million.
Xbrane develops organic medicine primarily based on a patented platform know-how that gives considerably decrease manufacturing prices in comparison with competing programs. Xbrane has a portfolio of biosimilar candidates focusing on EUR 53 billion in estimated annual peak gross sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched through the first quarter 2023. Xbrane’s head workplace is in Solna, simply exterior Stockholm.
Pareto Securities acted as sole supervisor and bookrunner. Baker McKenzie acted as authorized advisor with a world capital markets group consisting of Joakim Falkner, Johanna Flink, Olof Larsson, Carl Bohman and Carl Isaksson in Stockholm in addition to Adam Farlow, James Tanner and Madeleine Barrow in London.